Skip to content

Allphase Pharma Consulting, LLC

A Professional Service Provider for the Pharma Industry

Allphase Pharma Consulting, LLC
Menu

Primary menu

  • CONTACT
  • BLOGS
    • The Viewpoint
    • The News
    • Recent Literature
    • Did you know…?
    • QIDP Antibiotics
  • LEGAL
  • WELCOME

Secondary menu

  • The News
  • The Viewpoint
  • Did you know…?
  • Recent Literature
  • QIDP Antibiotics

Tag Archives: liposomal amphotericin

Two New Antifungals Presented at ICAAC San Diego

Posted on September 29, 2015 by Harald — No Comments ↓

As noticed by many other colleagues, ICAAC 2015 was a shadow of its former self.  Few participants overall, fewer posters, and even fewer exhibitors.  Reviewing the posters, there were relatively few from industry, most came from university or small research labs.  In a way, ICAAC 2015 was a true reflection of Continue reading Two New Antifungals Presented at ICAAC San Diego→

Share this:

  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to print (Opens in new window) Print
  • Click to email a link to a friend (Opens in new window) Email
  • Click to share on WhatsApp (Opens in new window) WhatsApp

Like this:

Like Loading...
Posted in QIDP Antibiotics, Recent Literature, The News | Tagged antibiotic blog, ASM Microbe, aspergillus, dihydroorotate dehydrogenase, encochleated amphotericin, F-901318, F2F Ltd., FDA, fungicidal, Fusarium, ICAAC, liposomal amphotericin, MAT-2203, Matinas BioPharma, mold infection, new antifungal class, oral Amphotericin, orotimide, RES system, Scedosporium | Leave a reply

Go back

Your message has been sent

Rating(required)
Warning

Footer Menu

Footer menu

  • CONTACT
  • BLOGS
  • LEGAL
  • WELCOME
  • Email
Copyright © 2026 Allphase Pharma Consulting, LLC. All Rights Reserved.
Theme: Catch Box by Catch Themes
Scroll Up
%d